Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common stock, par value $0.00001 per share
-
Shares outstanding
-
52,942,731
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
47,470,437
-
Shares change
-
+1,136,682
-
Total reported value, excl. options
-
$1,096,597,184
-
Value change
-
+$15,190,740
-
Number of buys
-
62
-
Number of sells
-
-31
-
Price
-
$23.1
Significant Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) as of Q4 2021
112 filings reported holding PMVP - PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share as of Q4 2021.
PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47,470,437 shares
of 52,942,731 outstanding shares and own 89.66% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7,330,423 shares), INTERWEST VENTURE MANAGEMENT CO (3,234,911 shares), JPMORGAN CHASE & CO (3,167,222 shares), RTW INVESTMENTS, LP (2,980,960 shares), BOXER CAPITAL, LLC (2,838,236 shares), VANGUARD GROUP INC (2,647,946 shares), BlackRock Inc. (2,539,824 shares), Euclidean Capital LLC (2,336,909 shares), VIKING GLOBAL INVESTORS LP (1,790,284 shares), and RA CAPITAL MANAGEMENT, L.P. (1,710,265 shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.